Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients

Table 3

Treatment-related costs of trabectedin and ifosfamide, for the average number of treatment cycles (see Table 2).

Treatment-related costs			Trabectedin		Ifosfamide
Unit	Price	Source	Use	Costs	Use	Costs
Trabectedin 1 mg vial	€1,956	[9]	2.17	€4,238	—	—
Trabectedin 0.25 mg vial	€506	[9]	1.85	€938	—	—
Ifosfamide 2 mg vial	€121	[9]	—	—	8.87	€1,070
Dexamethasone 20 mg vial	€9	[9]	1	€9	—	—
Granisetron 1 mg vial	€4	[9]	2	€8	4	€16
Dexamethasone 8 mg vial	€3	[9]	1	€3	4	€11
Mesna 0.4 mg vial	€9	[9]	—	—	1	€718
Hospitalization per day	€494	[7]	1	€494	5	€2,470
Full laboratory test	€43	[10]	1	€43	1	€43
Haematological test	€18	[10]	0.25	€5	0.25	€5
CT scan	€157	[11]	0.25	€71	0.25	€71
MRI scan	€264	[11]	0.25	€13	0.25	€13
Blood transfusion	€224	[7]	0.25	€56	0.25	€56
Drug costs per cycle
Drug acquisition costs				€5,175		€1,070
Drug administration costs				€702		€3,403
Drug costs, total per cycle				€5,877		€4,474
One-time treatment costs
CVC insertion	€1,015	[11]	1	€1,015	0.30	€305
Total treatment costs
(i) L-Sarcoma				€36,895		€17,081
(ii) Non-L-sarcoma				€23,595		€15,601

Mesna: 2-mercaptoethanesulfonate sodium.